Claire Palles

Title: **Claire Palles: A Pioneer in Predicting 5-Fluorouracil Toxicity**

Introduction

Claire Palles is an innovative inventor located in Oxford, GB, known for her contributions to the field of pharmacogenomics. She has made significant strides in developing methods that aid in predicting the risk of toxicity associated with the chemotherapy drug 5-fluorouracil (FU). Her dedication to improving patient outcomes highlights her commitment to advancing medical science.

Latest Patents

Palles holds a patent for a novel method of determining the risk of 5-fluorouracil toxicity. This invention provides an assay useful in predicting whether a subject may experience adverse reactions to FU treatment. The method screens for the presence of specific TYMS and DPYD polymorphisms, which are genetic variations that can influence drug metabolism. If one or more of these polymorphisms are present, it indicates an increased risk of developing toxicity; conversely, a negative result suggests a decreased risk.

Career Highlights

Claire Palles is affiliated with Oxford University Innovation Limited, where she applies her expertise in pharmacology and genetics to enhance patient care. Her innovative approach to research has garnered attention in the medical community, making her a notable figure in pharmacogenetic studies and personalized medicine.

Collaborations

Throughout her career, Palles has collaborated with esteemed colleagues such as David Kerr and Ian Tomlinson. These partnerships have fostered a multidisciplinary approach to research, allowing for comprehensive studies that integrate various aspects of medicine, genetics, and patient safety.

Conclusion

Claire Palles stands out as a valuable inventor in the realm of medical innovations. Her pioneering work on the risk of 5-fluorouracil toxicity exemplifies the critical intersection of science and patient care. With her ongoing contributions and collaborations, Palles continues to inspire advancements in healthcare and personalized treatment strategies.